Viral safety of C1-inhibitor NF

Biologicals

Volumn 35, Issue 3, 2007, Pages 173-181

  Terpstra, F G ^a   Kleijn, M ^b   Koenderman, A H L ^b   Over, J ^b   van Engelenburg, F A C ^a,b   Schuitemaker, H ^a   van 't Wout, A B ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Sanquin Plasmaproducten   (Netherlands)

Author keywords

C1 inhibitor; Nanofiltration; Pasteurization; PEG precipitation; Viral safety

Indexed keywords

CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BOVINE VIRAL DIARRHEA VIRUS; CONTROLLED STUDY; DRUG PURIFICATION; DRUG PURITY; HEPATITIS A VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; NANOFILTRATION; NONHUMAN; PARVOVIRUS; PASTEURIZATION; PRIORITY JOURNAL; PSEUDORABIES HERPETOVIRUS; VIRAL CONTAMINATION; VIRUS; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS TRANSMISSION;

ANIMALS; BIOLOGICAL PRODUCTS; CATTLE; CELL LINE; COMPLEMENT C1 INACTIVATOR PROTEINS; DIARRHEA VIRUSES, BOVINE VIRAL; DISINFECTION; DOGS; DRUG CONTAMINATION; FILTRATION; HEPATITIS A VIRUS; HERPESVIRUS 1, SUID; HIV; HUMANS; NANOTECHNOLOGY; PARVOVIRUS, CANINE; POLYETHYLENE GLYCOLS; PRECIPITATION; SAFETY; SERPINS; SWINE; VIRUSES;

BOVINE VIRAL DIARRHEA VIRUS 1; CANINE PARVOVIRUS; HEPATITIS A VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; SUID HERPESVIRUS 1;

EID: 34249989360     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2006.08.005     Document Type: Article

References (27)

1. Farrugia A., and Robert P. Plasma protein therapies: current and future perspectives. Best Pract Res Clin Haematol 19 (2006) 243-258
2. Zuraw B.L. Current and future therapy for hereditary angioedema. Clin Immunol 114 (2005) 10-16
3. Caliezi C., Wuillemin W.A., Zeerleder S., Redondo M., Eisele B., and Hack C.E. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 52 (2000) 91-112
4. Chiavetta J.A., Escobar M., Newman A., He Y., Driezen P., Deeks S., et al. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. CMAJ 169 (2003) 767-773
5. Pillonel J., and Laperche S. Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of Nucleic Acid Testing. Transfus Clin Biol 11 (2004) 81-86
6. German Federal requirements "Requirements of validation studies for demonstrating the virus safety of medicinal products derived from human blood plasma" (Bundesanzeiger Nr. 84, Mai 1994).
7. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. (Internet). CPMP/BWP/268/95 (1996), The European Agency for the Evaluation of Medicinal Products, London. Available from
8. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on plasma-derived medicinal products (2001), The European Agency for the Evaluation of Medicinal Products, London. CPMP/BWP/269/95, Rev. 3 Available from
9. Montgomery D.C. Design and analysis of experiments. 4th edition (1996), John Wiley & Sons, Inc., New York
10. Terpstra F.G., Parkkinen J., Tolo H., Koenderman A.H., Ter Hart H.G., von Bonsdorff L., et al. Viral safety of Nanogam(R), a new 15 nm-filtered liquid immunoglobulin product. Vox Sang 90 (2006) 21-32
11. Hilfenhaus J., and Nowak T. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate. Vox Sang 67 Suppl. 1 (1994) 62-66
12. Murphy P., Nowak T., Lemon S.M., and Hilfenhaus J. Inactivation of hepatitis A virus by heat treatment in aqueous solution. J Med Virol 41 (1993) 61-64
13. Nowak T., Niedrig M., Bernhardt D., and Hilfenhaus J. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation. Dev Biol Stand 81 (1993) 169-176
14. Yunoki M., Tsujikawa M., Urayama T., Sasaki Y., Morita M., Tanaka H., et al. Heat sensitivity of human parvovirus B19. Vox Sang 84 (2003) 164-169
15. Blumel J., Schmidt I., Willkommen H., and Lower J. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 42 (2002) 1011-1018
16. Burnouf T., and Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 9 (2003) 24-37
17. O'Grady J., Losikoff A., Poiley J., Fickett D., and Oliver C. Virus removal studies using nanofiltration membranes. Dev Biol Stand 88 (1996) 319-326
18. Van Holten R.W., Ciavarella D., Oulundsen G., Harmon F., and Riester S. Incorporation of an additional viral-clearance step into a human immunoglobulin manufacturing process. Vox Sang 83 (2002) 227-233
19. Mazurier C., Poulle M., Samor B., Hilbert L., and Chtourou S. In vitro study of a triple-secured von Willebrand factor concentrate. Vox Sang 86 (2004) 100-104
20. Troccoli N.M., McIver J., Losikoff A., and Poiley J. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. Biologicals 26 (1998) 321-329
21. Lee D.C., Stenland C.J., Miller J.L., Cai K., Ford E.K., Gilligan K.J., et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 41 (2001) 449-455
22. Stenland C.J., Lee D.C., Brown P., Petteway Jr. S.R., and Rubenstein R. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. Transfusion 42 (2002) 1497-1500
23. Tateishi J., Kitamoto T., Ishikawa G., and Manabe S. Removal of causative agent of Creutzfeldt-Jakob disease (CJD) through membrane filtration method. Membrane 18 (1993) 357-362
24. Tateishi J., Kitamoto T., Mohri S., Satoh S., Sato T., Shepherd A., et al. Scrapie removal using Planova virus removal filters. Biologicals 29 (2001) 17-25
25. WHO Consultation Meeting on Tissue Infectivity Distribution in TSE's, September 2005, London 2006.
26. Foster P.R., Welch A.G., McLean C., Griffin B.D., Hardy J.C., Bartley A., et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 78 (2000) 86-95
27. Golker C.F., Whiteman M.D., Gugel K.H., Gilles R., Stadler P., Kovatch R.M., et al. Reduction of the infectivity of scrapie agent as a model for BSE in the manufacturing process of Trasylol. Biologicals 24 (1996) 103-111